Navigation Links
Amylin Pharmaceuticals to Webcast Second Quarter Results
Date:7/14/2009

SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the second quarter of 2009 on Tuesday, July 21, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the second quarter of 2009.

The call will be webcast live through Amylin's corporate Web site and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 783-2141 (U.S./Canada) or (857) 350-1600 (international), Conference ID# 46259840. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 286-8010 (U.S./Canada) or (617) 801-6888 (international), Conference ID# 67467542.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
2. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
3. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
4. Amylin Announces Preliminary Tabulation of Annual Meeting Results
5. Amylin Responds to Eastbourne Letter
6. Amylin Comments on RiskMetrics Report
7. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
8. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
9. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
10. Amylin Issues Statement in Response to Carl Icahn
11. Icahn Asks Amylin to Allow Discussions With Eastbourne
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... FL (PRWEB) , ... February 21, 2017 , ... ... enables healthcare organizations to build connected digital health applications, announced a partnership with ... enable users to seamlessly connect to many clinical systems while keeping data secure ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics workflow ... joined its executive team to lead the development and commercialization of its Cancer ... improve the diagnosis and treatment of cancer. The CIDT addresses the need for ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... manufacturing facility at its headquarters laboratory in Poway, California. Based upon 12 ... of both in-house personnel and consultants, VetStem constructed and validated a state-of-the-art GMP ...
(Date:2/21/2017)... 21, 2017  Lexus, a returning partner of the Amgen ... and exclusive automobile partner of the men,s and women,s events for ... The 2017 Amgen Tour of California will ... of the best professional cycling teams in the world racing from ... four-day Amgen Breakaway from Heart Disease TM Women,s ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/1/2017)... BOSTON, Massachusetts , February 1, 2017 ... and events on emerging technology, announces the availability of a new ... Continue Reading ... ... systems in industrial and collaborative robots. Source: IDTechEx Report "Sensors for ...
Breaking Biology News(10 mins):